Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

15 results about "Rosacea flaccida" patented technology

Topical Benzimidazole Formulations and Methods for Use in Treating Inflammatory Dermatoses

Compositions and methods for treating and preventing inflammatory and autoimmune skin conditions, particularly rosacea, using one or more topically applied benzimidazole compounds in a pharmaceutically acceptable carrier for use on skin. A preferred benzimidazole compound comprises mebendazole. A treatment composition preferably comprises 0.05-0.075 weight percent mebendazole, and may comprise up to 20.0% mebendazole, in an aqueous carrier or vehicle comprising a cream, gel, lotion, liquid, emulsion, aerosol spray, non-aerosol spray,, suspension, or ointment and is applied at least once daily over a treatment period of at least two weeks to result in a reduction of cutaneous cytotoxic CD+8 T-cells, papules, pustules, swelling, appearance of redness or inflammation, and / or reduction in itchiness, and hot or burning sensation in the affected area compared to pre-treatment levels.
Owner:JJR&D LLC

Topical benzimidazole formulations and methods for use in treating inflammatory dermatoses

PCT designated stageWO2025221973A1Solution deliveryPharmaceutical non-active ingredientsPimpleInflammatory dermatosis
Compositions and methods for treating and preventing inflammatory and autoimmune skin conditions, particularly rosacea, using one or more topically applied benzimidazole compounds in a pharmaceutically acceptable carrier for use on skin. A preferred benzimidazole compound comprises mebendazole. A treatment composition preferably comprises 0.05-0.075 weight percent mebendazole, and may comprise up to 20.0% mebendazole, in an aqueous carrier or vehicle comprising a cream, gel, lotion, liquid, emulsion, aerosol spray, non-aerosol spray,, suspension, or ointment and is applied at least once daily over a treatment period of at least two weeks to result in a reduction of cutaneous cytotoxic CD+8 T-cells, papules, pustules, swelling, appearance of redness or inflammation, and / or reduction in itchiness, and hot or burning sensation in the affected area compared to pre-treatment levels.
Owner:JJR&D LLC

Composition

To provide a composition for use in the treatment or prevention of pathogenic infections, rosacea, eczema and psoriasis in humans or animals.SOLUTION: There is provided a composition comprising benzalkonium halide; didecyldimethylammonium halide; polyhexamethylene biguanide salt; bronopol; and p-chloro-m-cresol.SELECTED DRAWING: None
Owner:JVS PRODUCTS LIMITED

Topical benzimidazole formulations and methods for use in the treatment of inflammatory skin diseases

【Solution】A composition and method for treating and preventing inflammatory and autoimmune skin conditions, particularly rosacea, using one or more topically applied benzimidazole compounds in a pharmaceutically acceptable carrier for use on the skin. Preferred benzimidazole compounds include mebendazole. The therapeutic composition preferably contains 0.05 to 0.20% by weight of mebendazole in an aqueous or non-aqueous carrier or vehicle including creams, gels, lotions, liquids, emulsions, microemulsions, aerosol sprays, non-aerosol sprays, serums, solutions, suspensions, or ointments, may contain up to 20.0% of mebendazole, and is applied at least once a day over a treatment period of at least two weeks, resulting in a reduction in the appearance of skin cytotoxic CD+8 T cells, papules, pustules, swelling, redness or inflammation, and / or itching at the affected site compared to pre-treatment levels.
Owner:JJR&D LLC

Minocycline for use for the treatment of rosacea

PCT designated stageWO2026096776A1Tetracycline active ingredientsCapsule deliveryLesion countPharmaceutical drug
A pharmaceutical composition for treating moderate or severe rosacea comprises a formulated, body weight-independent low dose of minocycline that reduces the severity of rosacea in at least 2 weeks with a decrease in lesion count, Investigator's Global Assessment (IGA) score, and Clinician's Erythema Assessment (CEA) score with a measured improvement in quality of life.
Owner:JOURNEY MEDICAL CORP

Compositions for sebum control

The invention provides a composition comprising oleanolic acid and the salts, prodrug and solvates thereof; and one or more compounds selected from the following group: ellagic acid, adenine, betaine, choline, miquelianin, p-coumaric acid, pipecolic acid, protocatechuic acid and tyramine, and the salts, prodrugs and solvates thereof. Such a composition is for use in reducing lipid levels in sebocytes, and the composition may find use in treating acne vulgaris and rosacea.
Owner:DYSON OPERATIONS PTE LTD

Enhanced dermal penetration of lipophilic adapalene esters

PCT designated stageWO2026064807A2Organic active ingredientsPharmaceutical delivery mechanismMicroorganismRosacea flaccida
Methods for enhanced dermal delivery of adapalene esters to treat skin conditions including acne, rosacea, and photoaging are described. The invention is based on the discovery that applying lipophilic adapalene esters to non-disinfected skin and / or with preserved natural microflora results in significantly enhanced penetration and therapeutic and non-therapeutic efficacy compared to conventional protocols involving preliminary skin disinfection. The methods avoid antimicrobial pretreatments, preserve beneficial skin microorganisms, and achieve high absorption and penetration of the adapalene ester while maintaining safety and reducing treatment complexity.
Owner:ACTERA INGREDIENTS INC

Prevention of rosacea inflammation

The disclosure demonstrates the role of mast cell stabilizers in treating rosacea. The disclosure also shows the role of mast cells, cathelicidin, serine protease and / or vitamin D3 in rosacea pathology and the use of antagonists and inhibitors thereof to treat rosacea.
Owner:RGT UNIV OF CALIFORNIA

Method for treating acne and other inflammatory skin conditions

A method for treating active acne or any other inflammatory skin condition, such as, but not limited to, rosacea, psoriasis, and the like is disclosed comprising using a microneedling device capable of achieving certain specific depths which are controllable by the user and a medical grade anti-inflammatory antibacterial antioxidant oil which is applied to the treatment area both before and after the microneedling. In a preferred embodiment, the oil is a medical grade CBD tincture with organic hempseed oil. The treatment is repeated until satisfactory resolution of the acne or any other inflammatory skin condition that is being treated has been achieved.
Owner:HEALMD LLC

Novel skin care composition for treating atopic dermatitis

PendingUS20260027164A1Cosmetic preparationsAntipyreticAtopic dermatitisRosacea flaccida
The present invention generally relates to the field of skin care. More particularly. the invention relates to a cosmetic or therapeutic skin care composition comprising at least one of the skin-health promoting Staphylococcus strains selected from the group of Staphylococcusepidermidis HAC26 and Staphylococcus warneri HAA333 or a culture supernatant of any of these. The invention also provides a method for treating or preventing atopic dermatitis and / or rosacea by applying the skin care composition of the invention to a skin area in need of treatment. The invention also relates to the use of a skin care composition of the invention for treating or preventing atopic dermatitis and / or rosacca.
Owner:BEIERSDORF AG

Stabilized oxymetazoline formulations and their uses

The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.
Owner:MAYNE PHARMA LLC

Novel antimicrobial peptides and their pharmaceutical compositions

The present invention provides an antimicrobial peptide and its pharmaceutical composition that is highly stable, safe, has good antimicrobial activity, and has a shorter sequence, and can treat and alleviate rosacea, adolescent acne, atopic dermatitis, genital warts and vulvar intraepithelial neoplasia, inflammatory reactions, inflammatory response syndromes, etc., and the antimicrobial polypeptide contains the amino acid sequence Ac-SRMKKWAKIIEKWRKWH-NH2.
Owner:QINGDAO SENSHENG BIOPHARMACEUTICAL TECH CO LTD

Topical skin care compositions

Disclosed are compositions and their use for the treatment of human skin, particularly facial skin, to alleviate the symptoms of cosmetic or dermatologic skin conditions. The compositions include black willow bark extract, cats claw extract, and dragon's blood extract. The compositions ameliorate skin conditions including acne, rosacea, blemish, dermatitis, eczema, or the like.
Owner:M & J PROPERTIES JOINT VENTURE

Process for obtaining inula helenium extracts and the use, in particular cosmetic use, thereof for skin care

PCT designated stageWO2026132055A1Organic active ingredientsCosmetic preparationsHeleniumPharmacology
The present invention relates to processes for obtaining a plant extract of flowering tops of Inula helenium, and also to Inula helenium plant extracts, to compositions comprising same, and to the uses thereof for preventing and / or treating a chronic inflammatory skin disorder, in particular a pigmentary disorder, in particular (i) a pigmentary spot, in particular an actinic lentigo, (ii) a post-inflammatory hyperpigmentation, in particular associated with a scar or with an unaesthetic disorder consecutive to an inflammatory skin manifestation, in particular a scar or an acne mark, a scar or a rosacea mark or (iii) melasma.
Owner:LOREAL SA